{
    "clinical_study": {
        "@rank": "97448", 
        "arm_group": {
            "arm_group_label": "omeprazole", 
            "arm_group_type": "Experimental", 
            "description": "Omeprazole 20 mg (oral route) twice a day will be given to the subjects for one week. This intervention will be compared with ranitidin 150 mg (oral route) twice a day."
        }, 
        "brief_summary": {
            "textblock": "Previous reports have shown a possible drug interaction between clopidogrel and proton pump\n      inhibitors (PPI\u00b4s), which could result in increased number of adverse cardiovascular events\n      among patients on dual antiplatelet therapy(DAPT). Because of this, ranitidin has been\n      proposed as an alternative drug  to PPI\u00b4s for prophylaxis of gastrointestinal bleeding in\n      patients who need DAPT. The study\u00b4s aim is to test the hypothesis that ranitidin doesn\u00b4t\n      have any influence on clopidogrel pharmacodynamic."
        }, 
        "brief_title": "Ranitidin Versus Omeprazole in Patients Taking Clopidogrel", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "VA Drug Interactions [VA Drug Interaction]", 
        "condition_browse": {
            "mesh_term": "Coronary Disease"
        }, 
        "detailed_description": {
            "textblock": "Study population: 100 patients with Stable Coronary Artery Disease from Heart Institute\n\n      Inclusion Criteria:\n\n        -  Age > 18 years old\n\n        -  Coronary artery disease, defined as previous myocardial infarction and/or coronary\n           angioplasty and/or CABG surgery and/or coronariography showing obstruction of at least\n           50 % in one of major epicardial vesses\n\n        -  Treatment with Acetylsalicylic Acid (ASA) 100 mg/day\n\n      Exclusion Criteria:\n\n        -  Use in the last 7 days of oral anticoagulant or any other antiplatelet drug beside ASA\n\n        -  Previous utilization of PPI or ranitidine in the last 7 days before randomization\n\n        -  Active bleeding\n\n        -  Pregnancy or woman of childbearing age without contraceptive method\n\n        -  Hemoglobin < 10 g/dL or hematocrit < 30 %, hematocrit > 50 %, platelets < 100.000/mm3\n           or > 500.000/mm3; creatinin clearance < 50 ml/minute\n\n        -  Percutaneous coronary intervention (PCI) on the last 30 days before randomization (or\n           PCI on the last year when drug-eluted stents are used); CABG surgery on the last 90\n           days; acute coronay syndrome on the last 60 days\n\n        -  Active malignant neoplasm\n\n        -  Active peptic ulcer disease on the last 60 days or upper gastrointestinal bleeding any\n           time in life\n\n        -  Known allergy to the drugs clopidogrel, ranitidine or omeprazole\n\n        -  Refuse to participate in the study]\n\n      Methodology: The study has a double-blind, double-dummy prospective design. Clopidogrel\n      action is evaluated by platelet function tests: VerifyNow, bioimpedance aggregometry and\n      PFA-100. The patients  have measurements of platelet function on three moments: before\n      starting clopidogrel; 1 week after DAPT with clopidogrel (without loading dose) plus ASA;\n      and after 1 week of randomization to ranitidin 150 mg bid or omeprazole 20 mg bid."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age > 18 years old\n\n          -  Coronary artery disease, defined as previous myocardial infarction and/or coronary\n             angioplasty and/or CABG surgery and/or coronariography showing obstruction of at\n             least 50 % in one of major epicardial vesses\n\n          -  Treatment with Acetylsalicylic Acid (ASA) 100 mg/day\n\n        Exclusion Criteria:\n\n          -  Use on the last 7 days of any other antiplatelet drug beside ASA or oral\n             anticoagulant\n\n          -  Previous utilization of PPI or ranitidine in the last 7 days before randomization\n\n          -  Any active bleeding\n\n          -  Pregnancy or woman of childbearing age without contraceptive method\n\n          -  Hemoglobin < 10 g/dL or hematocrit < 30 %, hematocrit > 50 %, platelets < 100.000/mm3\n             or > 500.000/mm3; creatinin clearance < 50 ml/minute\n\n          -  Percutaneous coronary intervention (PCI) on the last 30 days before randomization (or\n             PCI on the last year when drug-eluted stents are used); CABG surgery on the last 90\n             days; acute coronay syndrome on the last 60 days\n\n          -  Active malignant neoplasm\n\n          -  Active peptic ulcer disease on the last 60 days or upper gastrointestinal bleeding\n             any time in life\n\n          -  Known allergy to the drugs clopidogrel, ranitidine or omeprazole\n\n          -  Refuse to participate in the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01896557", 
            "org_study_id": "0136/11"
        }, 
        "intervention": {
            "arm_group_label": "omeprazole", 
            "description": "Influence of omeprazole on clopidogrel pharmacodynamics will be evaluated.", 
            "intervention_name": "omeprazole", 
            "intervention_type": "Drug", 
            "other_name": [
                "Peprazol", 
                "Losec", 
                "PPI"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Omeprazole", 
                "Ranitidine", 
                "Ranitidine bismuth citrate", 
                "Clopidogrel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "clopidogrel", 
            "omeprazole", 
            "ranitidin", 
            "interaction", 
            "aggregability"
        ], 
        "lastchanged_date": "July 10, 2013", 
        "number_of_arms": "1", 
        "official_title": "Possible Drug Interaction Between Clopidogrel and Ranitidin or Omeprazole in Patients With Stable Coronary Heart Disease: a Comparative Study", 
        "other_outcome": {
            "description": "The main outcome will be compared on pre-specified subgroups:\nelderly (age > 65 yrs-old) versus non-elderly\nmale versus female\nsmoking versus non-smoking patients\nobese (BMI > 30 kg/m2) versus non-obese\ndiabetic versus non-diabetic\npatients in use or not in use of statins\npresence or not of genetic polymorphisms on cytochrome CYP2C19.", 
            "measure": "Comparing the main outcome on pre-specified subgroups", 
            "safety_issue": "No", 
            "time_frame": "1 week after drug exposure"
        }, 
        "overall_official": {
            "affiliation": "Director of Acute Coronary Care Unit", 
            "last_name": "Jos\u00e9 C Nicolau, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Brazil: National Committee of Ethics in Research", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "One week after starting double-blind, double-dummy, randomized therapy with ranitidin or omeprazole on patients treated with DAPT, platelet function will be compared with the method VerifyNow(Accumetrics - USA).", 
            "measure": "Comparing platelet function of patients on dual antiplatelet therapy with ASA + clopidogrel, between the groups ranitidin and omeprazole, using VerifyNow method.", 
            "safety_issue": "No", 
            "time_frame": "1 week after drug exposure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01896557"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "After 1 week of randomization to ranitidin or omeprazole, the platelet function will also be analysed by two other methods: PFA-100 (Siemens-USA) and bioimpedance aggregometry.", 
            "measure": "Comparison of the primary outcome with other two methods of platelet aggregability: PFA-100 and bioimpedance aggregometry", 
            "safety_issue": "No", 
            "time_frame": "1 week after drug exposure"
        }, 
        "source": "University of Sao Paulo General Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "InCor Heart Institute", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Sao Paulo General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2011", 
        "study_design": "Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2011"
    }
}